Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etrolizumab - Genentech

Drug Profile

Etrolizumab - Genentech

Alternative Names: Monoclonal antibody beta7; PRO145223; recombinant-human-monoclonal-antibody-beta7; RG 7413; rhu-monoclonal-antibody-beta7; rhuMAb Beta7; rhuMAb β7; RO 5490261

Latest Information Update: 21 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Roche
  • Class Antiulcers; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Alpha4beta7 integrin antagonists; Integrin alphaEbeta7 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis

Most Recent Events

  • 20 Oct 2018 Preliminary efficacy data from the phase III BERGAMOT trial in Crohn's-disease presented at the 26th United European Gastroenterology Week (UEGK-2018)
  • 09 Apr 2018 Genentech completes a phase I trial in Healthy volunteers in USA (SC) (NCT02996019)
  • 13 Mar 2018 Phase-I clinical trials in Crohn's disease (In children, In adolescents) in Spain, Poland (SC) (NCT03478956) (EudraCT2017-003649-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top